Legend Capital-backed clinical services provider R&G Pharmastudies floated in a $174m initial public offering while several corporates exited Pymetrics in an acquisition by Harver.

Public markets Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, has exited China-based contract clinical services provider R&G Pharmastudies in a $174m initial public offering on Shenzhen Stock Exchange’s Chinext market. The firm did not disclosed how much funding it had provided for R&G but said it first invested through a 2017…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.